Shannon R Kenney1, Bradley J Anderson2, Genie L Bailey3, Michael D Stein4. 1. Behavioral Medicine Department, Butler Hospital, Providence, RI 02906, United States of America; Warren Alpert Medical School of Brown University, Providence, RI, 02912, United States of America. Electronic address: Shannon_Kenney@brown.edu. 2. Behavioral Medicine Department, Butler Hospital, Providence, RI 02906, United States of America. 3. Warren Alpert Medical School of Brown University, Providence, RI, 02912, United States of America; Stanley Street Treatment & Resources, Inc, Fall River, MA 02720, United States of America. 4. Behavioral Medicine Department, Butler Hospital, Providence, RI 02906, United States of America; Boston University School of Public Health, Boston, MA 02118, United States of America.
Abstract
BACKGROUND: In the current study, we examined factors predicting willingness to receive buprenorphine treatment and preferences for various buprenorphine formulations (oral, injection, implant) among persons in opioid withdrawal management. METHODS: Participants were three hundred thirty-eight persons entering brief inpatient opioid withdrawal management programs at two sites. We used t-tests and Pearson χ2 - tests of independence to compare participants willing and unwilling to be prescribed buprenorphine in the future. Among persons willing to receive buprenorphine, we used multinomial logistic regression to estimate the adjusted effects of potential correlates of type of buprenorphine formulation preferred. RESULTS: Participants averaged 33.9 (±9.5) years of age, 70.4% were male, 82.8% were White, and 11.0% were Latino/a. In all, 55.6% of participants had been prescribed buprenorphine in the past, and 54.7% were willing to use prescribed buprenorphine in the future. Those reporting past month illicit buprenorphine use and prior overdose were more willing to use prescribed buprenorphine. Of these (n = 180), most preferred daily buprenorphine formulations (tablet or film) (48.6%) over a weekly or monthly injection (23.1%) or bi-annual implant (28.3%). CONCLUSIONS: Past buprenorphine prescription does not predict future willingness to restart. Among those willing to use buprenorphine, newer formulations of buprenorphine appealed to more than half of the participants.
BACKGROUND: In the current study, we examined factors predicting willingness to receive buprenorphine treatment and preferences for various buprenorphine formulations (oral, injection, implant) among persons in opioid withdrawal management. METHODS:Participants were three hundred thirty-eight persons entering brief inpatient opioid withdrawal management programs at two sites. We used t-tests and Pearson χ2 - tests of independence to compare participants willing and unwilling to be prescribed buprenorphine in the future. Among persons willing to receive buprenorphine, we used multinomial logistic regression to estimate the adjusted effects of potential correlates of type of buprenorphine formulation preferred. RESULTS:Participants averaged 33.9 (±9.5) years of age, 70.4% were male, 82.8% were White, and 11.0% were Latino/a. In all, 55.6% of participants had been prescribed buprenorphine in the past, and 54.7% were willing to use prescribed buprenorphine in the future. Those reporting past month illicit buprenorphine use and prior overdose were more willing to use prescribed buprenorphine. Of these (n = 180), most preferred daily buprenorphine formulations (tablet or film) (48.6%) over a weekly or monthly injection (23.1%) or bi-annual implant (28.3%). CONCLUSIONS: Past buprenorphine prescription does not predict future willingness to restart. Among those willing to use buprenorphine, newer formulations of buprenorphine appealed to more than half of the participants.
Authors: Chris-Ellyn Johanson; Cynthia L Arfken; Salvatore di Menza; Charles Roberts Schuster Journal: Drug Alcohol Depend Date: 2011-08-21 Impact factor: 4.492
Authors: Jason White; James Bell; John B Saunders; Paul Williamson; Maria Makowska; Aaron Farquharson; Katherine L Beebe Journal: Drug Alcohol Depend Date: 2009-04-28 Impact factor: 4.492
Authors: Chinazo O Cunningham; Robert J Roose; Joanna L Starrels; Angela Giovanniello; Nancy L Sohler Journal: J Addict Med Date: 2013 Jul-Aug Impact factor: 3.702
Authors: Elizabeth C Saunders; Sarah K Moore; Olivia Walsh; Stephen A Metcalf; Alan J Budney; Emily Scherer; Lisa A Marsch Journal: J Subst Abuse Treat Date: 2020-01-21
Authors: Matisyahu Shulman; Mei-Chen Hu; Maria A Sullivan; Sarah C Akerman; James Fratantonio; Vincent Barbieri; Edward V Nunes; Adam Bisaga Journal: Drug Alcohol Depend Date: 2022-02-02 Impact factor: 4.492
Authors: Elizabeth C Saunders; Alan J Budney; Patricia Cavazos-Rehg; Emily Scherer; Lisa A Marsch Journal: Prev Med Date: 2021-09-07 Impact factor: 4.018
Authors: Salomon Poliwoda; Nazir Noor; Jack S Jenkins; Cain W Stark; Mattie Steib; Jamal Hasoon; Giustino Varrassi; Ivan Urits; Omar Viswanath; Adam M Kaye; Alan D Kaye Journal: Health Psychol Res Date: 2022-08-20
Authors: Ricky N Bluthenthal; Kelsey Simpson; Rachel Carmen Ceasar; Johnathan Zhao; Lynn Wenger; Alex H Kral Journal: Drug Alcohol Depend Date: 2020-03-18 Impact factor: 4.492
Authors: Elizabeth Beaulieu; Catherine DiGennaro; Erin Stringfellow; Ava Connolly; Ava Hamilton; Ayaz Hyder; Magdalena Cerdá; Katherine M Keyes; Mohammad S Jalali Journal: Value Health Date: 2020-10-26 Impact factor: 5.725